However, the durability of response is limited [6] and tumour progression occurs after 6-7 months of monotherapy or around 9 months of combination therapy, indicating the development of compensatory mechanisms that antagonize mutant BRAF and MEK inhibition. The gene discussed is MAP2K7; the disease is neoplasm.